Latest Sunitinib Stories
Argos Therapeutics has initiated a Phase IIa trial of its AGS-003 therapy, in combination with sunitinib, for the treatment of newly diagnosed advanced renal cell carcinoma. Approximately 50 subjects with advanced renal cell carcinoma (RCC) will be enrolled in the Phase IIa trial.
By Martin Shipton A DAUGHTER whose father suffers from cancer has today appealed directly to Health Minister Edwina Hart for those in his position to be given the drugs that could prolong their lives.
Argos Therapeutics today announced the initiation of a Phase 2a trial of its AGS-003 therapy, in combination with sunitinib, for the treatment of newly diagnosed advanced renal cell carcinoma (RCC).
Campaigners battling for a cancer victim have been told their case is not exceptional enough.
Pfizer announced today that important study results involving the company's leading anticancer agent, SUTENT(R) (sunitinib malate), as well as data examining an investigational agent, CP-751,871, will be presented at the 33rd European Society for Medical Oncology (ESMO) Congress in Stockholm, 12--16 September 2008.
Cancer drug developer Antisoma has started a Phase II study of AS1411 in metastatic renal cell carcinoma. The single-arm trial will enroll around 30 patients intolerant to, or having relapsed after, previous treatments including a tyrosine kinase inhibitor (sunitinib or sorafenib).
By LYNDSAY MOSS HEALTH CORRESPONDENT PATIENTS should be allowed to pay privately for cancer drugs and still keep their free NHS care in certain cases, the Scottish Government indicated yesterday.
London, UK: 04 September 2008 - Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today announced that it has started a phase II study of AS1411 in metastatic renal cell carcinoma (kidney cancer).
By Emma Brady Midlands cancer patients are being kept in the dark about new treatments that could extend their lives, it was claimed today.
Leading UK cancer experts have accused a health watchdog of forcing patients to remortgage their homes to afford treatments freely available in Europe.